title: Advances in understanding pituitary tumors.
abstract: Pituitary tumors are common in the general population. Since neuroimaging techniques have improved, pituitary tumors are more often diagnosed incidentally. About 16.7% of the general population show changes in the pituitary gland. Predominantly, pituitary tumors are benign pituitary adenomas. Pituitary carcinomas or aggressive pituitary tumors are extremely rare. They might develop from benign adenomas. New genetic and epigenetic abnormalities help us to understand pituitary tumorigenesis and might lead to therapeutical targeting drugs in the future. Macroadenomas (>1 cm) can lead to visual field disturbances, compression of cranial nerves, hypopituitarism, and infiltration of the cavernous sinuses. The functional status of the pituitary tumor is important. About half to one third of all pituitary tumors are non-functioning pituitary adenomas. The other pituitary tumors show a specific pattern of hormone secretion. About 25% to 41% of all pituitary tumors are prolactinomas, acromegaly with production of growth hormone represents 10% to 15% of adenomas, Cushing's disease with production of adrenocorticotropic hormone accounts for 10%, and other hormonal characteristics are less common. Transsphenoidal resection and total adenomectomy are desirable. Radiosurgery has enriched the surgical treatment options. Surgical treatment is the intervention of choice except for prolactinomas, where pharmaceutical treatment is recommended. Pharmaceutical treatment consists of dopamine agonists such as cabergoline and somatostatin analogues that include octreotide and pasireotide; retinoic acid is of theoretical interest while peroxisome proliferator-activated receptor-gamma-ligands are not clinically useful. In acromegaly, pegvisomant is a further treatment option. Temozolomide should be considered in aggressive pituitary tumors. In general, pharmaceutical options developed recently have extended the repertoire of treatment possibilities of pituitary tumors.
authors.affiliation: Max Planck Institute of Psychiatry, Clinical Neurendocrinology Group Kraepelinstraße 2-10, 80804 Munich Germany.
authors.forename: Anna
authors.initials: A
authors.lastname: Kopczak
authors.affiliation: Max Planck Institute of Psychiatry, Clinical Neurendocrinology Group Kraepelinstraße 2-10, 80804 Munich Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Renner
authors.affiliation: Max Planck Institute of Psychiatry, Clinical Neurendocrinology Group Kraepelinstraße 2-10, 80804 Munich Germany.
authors.forename: Günter
authors.initials: G
authors.lastname: Karl Stalla